eltrekibart + mirikizumab

Eltrekibart + mirikizumab is an investigational **combination therapy of two monoclonal antibodies** undergoing evaluation for the treatment of moderately to severely active **ulcerative colitis** in adults. **Eltrekibart** is a monoclonal antibody with a mechanism of action not fully publicly disclosed, while **mirikizumab (brand name OMVOH, code name LY3074828)** is a monoclonal antibody that selectively targets the p19 subunit of interleukin-23, thereby inhibiting the IL-23 signaling pathway involved in chronic gut inflammation. Mirikizumab is **FDA-approved** for ulcerative colitis and Crohn’s disease, whereas eltrekibart is investigational. The combination is being investigated for synergistic or additive effects on disease remission in ulcerative colitis. Both agents are administered via injection or infusion[1][3][5][7][9].

Other names

mirikizumab-mrkz